Drugs / LFX453
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02052687 | Jan → Jun 2014 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 22 trials · 2 missed | ||||||
| Phase 2 | NCT02482428 | May 2015 → May 2016 | anogenital human papillomavirus infection | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 2 | NCT02404389 | Mar 2015 → Jan 2016 | actinic keratosis | Novartis Pharmaceuticals | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LFX453 | “LFX453 0.1% nanomedicinal cream (NMC) Twice daily applications for a maximum of 12 weeks” NCT02482428 ↗ |
| Route | Topical | “multiple topical applications” NCT02052687 ↗ |